Occam Places Jeff Goater as Board Chair of AviadoBio
AviadoBio, a pre-clinical stage platform company with operations in the UK and the US and backed by NEA, F-Prime, and J&J Innovation and focused on developing and delivering transformative gene therapies for people with neurodegenerative disorders, has appointed Jeff Goater as Chair of its Board of Directors.
Jeff brings more than 20 years of biotech and Wall Street experience to this appointment. Currently, Jeff is a Venture Partner at The Column Group and interim CEO of Atavistik Bio. Previous roles include CEO of Surface Oncology and Managing Director at Evercore Partners.
Jeff holds graduate degrees in immunology, pathology, and business administration from the University of Rochester. He currently serves on the boards of Atavistik, Judo Bio, Kallyope, Ribon Therapeutics, and Surface Oncology.
With Occam having also placed Lisa Deschamps as CEO at AviadoBio in 2021, we are pleased to extend our relationship at the Board level.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.